CN103417906B - Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof - Google Patents
Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof Download PDFInfo
- Publication number
- CN103417906B CN103417906B CN201210159099.0A CN201210159099A CN103417906B CN 103417906 B CN103417906 B CN 103417906B CN 201210159099 A CN201210159099 A CN 201210159099A CN 103417906 B CN103417906 B CN 103417906B
- Authority
- CN
- China
- Prior art keywords
- preparation
- depression
- parts
- treatment
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof, purposes particularly in preparation treatment cancer-related antidepressant agents, cantharides Chinese medicine composition of the present invention is made up of ten Herba indigoferae Pseudotinctoriae such as Mylabris, Radix Ginseng, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Sparganii, Herba Scutellariae Barbataes, the basis of Chinese medicine composition increases corresponding adjuvant adopts conventional method to obtain compound mylabris preparation, provides new medicine and expanded the clinical practice of compound mylabris preparation for depressive illness.
Description
Technical field
The present invention relates to cantharides Chinese medicine composition and the novelty teabag of preparation in preparation medicament for treatment of depression thereof, the purposes especially in preparation treatment tumor patient antidepressant agents.
Technical background
Depression, belong to affective disorder disease, that what to be caused by a variety of causes take depression as one group of mental maladjustment or the affective disorder of cardinal symptom, clinical manifestation be depressed, interest goes down, self evaluation is too low, disheartened to future, to be reluctant initiatively and people associates.Normal with corresponding thinking and behavior change, some patients there will be hallucination and vain hope, and severe patient, with suicide, has a strong impact on the quality of life of people.Majority of cases has the tendency of recurrent exerbation, and each outbreak great majority can be alleviated, and part can have residual symptoms or transfer to chronic.
Depression has at least the patient of 10% to occur maniac access, now should be diagnosed as bipolar disorders.Our depression of often saying in addition, in fact refers to major depression (major depression) clinically, has the people of 16% can affect by it in certain period throughout one's life in crowd.Suffer from depression except paying serious emotion and social costs, economic cost is also huge.According to World Health Organization's statistics, depression has become the large illness in the world the 4th, expects the year two thousand twenty, may become the second largest disease being only second to coronary heart disease.
Along with the quickening of social life rhythm, the increase of operating pressure, the sickness rate of depression is in ascendant trend year by year, and the early diagnosis of depression and treatment, more and more come into one's own.
In the middle of patients with depression, have a very special colony merited attention, that is exactly the depression problem of tumor patient.Research confirms, most of tumor patient also exists unhealthy emotion reaction, wherein common with depressive symptom, i.e. cancer-related depression (cancer related depression, CRD), the patient that causes referring to diagnosing malignant tumor, treat and produce in the process such as complication process loses the pathologic emotional response of individual spirit normality.On the one hand, the symptom of patients with depression is similar to some tumor patient, comprising not feeling like a meal, weight loss, insomnia, hebetude, loss of energy etc.On the other hand, depressive disorder again with malignant tumor height correlation, large percentages that both are altogether sick, malignant tumor patient occurs that depressive disorder can be caused by disease itself or chemotherapeutics, or the psychoreaction of the caused deformity of tumor again.Find according to epidemiological study, suffering from the depressed sickness rate of cancer-related in tumor patient is 18% ~ 50%, what may there is depressive symptom is 85.39%, and patients undergoing chemotherapy depression incidence is 32.5% ~ 75.7%, and the depressive emotion incidence rate of patients undergoing chemotherapy is 78.4% first.Meanwhile, cancer-related depression (CRD) has following characteristics, and incidence rate is high, discrimination is low, it is low to treat, quality of life is low.CRD drastically influence rehabilitation and the prognosis of tumor patient, and therefore studying tumor complicated depression has important realistic meaning.
At present, the multiplex Western medicine of modern medicine carrys out Cure of depression, but the western medicine cycle is long, toxic and side effects is large, greatly have impact on clinical efficacy.Therefore, go to inquire into the antidepressant effect developing Chinese medicine and prescription thereof from the angle of Chinese medicine to have broad prospects.
Compound mylabris preparation is for primary raw material with Mylabris, Radix Ginseng, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Sparganii, Herba Scutellariae Barbatae, Rhizoma Curcumae, Fructus Corni, Fructus Ligustri Lucidi, Fel Ursi powder, Radix Glycyrrhizae, extract the preparation that its extract with medical value is made as effective ingredient, there is removing blood stasis become thin, the effect of counteracting toxic substances phagedenoma, wherein FUFANG BANMAO JIAONANG is recorded in the Sanitation Ministry medicine standard Traditional Chinese medicine historical preparation the 17, is mainly used in primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor etc. clinically.
Present invention applicant respectively the patent No. be ZL200710200660.4, name is called that " compound cantharidin oral preparations and preparation method thereof " and the patent No. are ZL200710077864.3, name is called in the patent of invention of " compound cantharis liquid formulation and preparation method thereof ", discloses compound mylabris preparation prepared by ten a herbs such as Mylabris, Radix Ginseng, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosis and preparation method thereof.Although research before shows that compound mylabris preparation may be used for preparing the medicine of various disease conditions such as treatment tumor, immunity moderation etc., have no patent documentation and the research report of the therapeutical effect utilizing compound mylabris preparation to depression aspect.The applicant is also unexpected in research subsequently to be found, compound mylabris preparation may be used for the treatment of depressive illness, particularly has obvious therapeutic effect to tumor patient depression aspect.
Summary of the invention
The object of this invention is to provide a kind of cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof, the purposes especially in preparation treatment cancer-related antidepressant agents.
The traditional Chinese medical science finds the research of depression, from the traditional Chinese medical science in theory, insufficiency of kidney-YANG and depression have certain contacting.Kidney yang is all sun basis, the yang-energy of main the whole body, insufficiency of kidney-YANG, yang-energy loses agitates in warm, cause the not raw marrow of essence, marrow void can not fill brain, and brains are hollow, gods are lost and are supported and be disease, the kidney being the origin of congenital constitution, and Syndrome Differentiation of Chinese Medicine controls depression, should pay attention to " initiatively " function rousing oneself kidney yang, depressed all diseases must be improved better by the kidney warming sun, thus control depression for clinical distinguishing.
The prescription of compound mylabris preparation is: Mylabris, Radix Ginseng, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Sparganii, Herba Scutellariae Barbatae, Rhizoma Curcumae, Fructus Corni, Fructus Ligustri Lucidi, Fel Ursi powder, Radix Glycyrrhizae.Radix Ginseng, has strongly invigorating primordial QI, invigorating the spleen to benefit the lung, and promote the production of body fluid beneficial blood, calms the nerves and increases effect of intelligence, for vigour collapse card, lung spleen heart syndrome of deficiency of kidney-QI, calentura deficiency of vital energy Tianjin wound yearningly and diabete; The Radix Astragali, has effect of invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation, anorexia and loose stool, sinking of QI of middle-JIAO, exterior deficiency spontaneous perspiration weak for the deficiency of vital energy; Radix Et Caulis Acanthopanacis Senticosi, has the effect of replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization, inappetence, soreness of waist and knee joint, insomnia and dreamful sleep weak for deficiency of spleen-YANG and kidneyYANG, body void.Radix Glycyrrhizae, has invigorating the spleen and benefiting QI, nourishing the lung to arrest cough, removing toxic substances and in, be in harmonious proportion effects of hundred medicines, Fructus Ligustri Lucidi, belongs to tonic, has the effect of liver and kidney tonifying, this several medical material all belongs to tonify deficiency QI invigorating class medicine from classification of TCD, and Synergistic, has good effect to kidney-yang nourishing.Meanwhile, the cantharidin in side in Mylabris can suppress DNA and RNA to synthesize, and has stronger affinity to liver and cancerous cell.Effective to primary hepatic and other tumors, and without bone marrow inhibition, also there is leukocyte increasing number, antiviral, antiinflammatory action.11 kinds of medicines are dialectical to be treated, and has the effect of warming and recuperating the kidney-YANG, invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, repercussive eliminating stagnation while anticancer.
Compound mylabris preparation of the present invention, according to listed as parts by weight, be prepared from through extracting by raw material of Chinese medicine Mylabris 0.6-6 part, Radix Ginseng 1.5-15 part, Radix Astragali 7.5-100 part, Radix Et Caulis Acanthopanacis Senticosi 7.5-100 part, Rhizoma Sparganii 2.4-24 part, Herba Scutellariae Barbatae 9-100 part, Rhizoma Curcumae 2.4-24 part, Fructus Corni 3-30 part, Fructus Ligustri Lucidi 3-30 part, Fel Ursi powder 0.05-1.0 part, Radix Glycyrrhizae 1.5-15 part.
Most preferred proportioning is: Mylabris 3.97 parts, Radix Ginseng 9.92 parts, the Radix Astragali 49.58 parts, Radix Et Caulis Acanthopanacis Senticosi 49.58 parts, Rhizoma Sparganii 15.83 parts, Herba Scutellariae Barbatae 59.5 parts, Rhizoma Curcumae 15.83 parts, Fructus Corni 19.83 parts, Fructus Ligustri Lucidi 19.83 parts, Fel Ursi powder 0.4 part, 9.92 parts, Radix Glycyrrhizae.
When applying, medicine of the present invention can at least one pharmaceutically conventional carrier as required, as diluent, filler, binding agent, excipient, disintegrating agent, surfactant, absorption enhancer and lubricant etc.
Aforesaid compound mylabris preparation preferably uses with the form of capsule, injection, tablet, drop pill, granule, Emulsion, solution or suspending agent, is more preferably capsule.Above-mentioned dosage form all can be prepared according to the conventional method of pharmaceutical field.
The route of administration of aforesaid compound mylabris preparation is oral, percutaneous, vein or intramuscular injection.
In the preparation method of compound mylabris preparation of the present invention, its effective component extracts can adopt the extraction process of FUFANG BANMAO JIAONANG in the Sanitation Ministry medicine standard Traditional Chinese medicine historical preparation the 17 to extract, can be ZL200710200660.4 according to the patent No., name is called that the method for " compound cantharidin oral preparations and preparation method thereof " is extracted, also can be ZL200710077864.3 according to the patent No., name is called that the method in " compound cantharis liquid formulation and preparation method thereof " is extracted, can also extract by the method for routine.
The further experimental study of the applicant finds, compound mylabris preparation really can be used for the medicine preparing Cure of depression, especially for the medicine of preparation treatment tumor patient depression.
In order to make those of ordinary skill in the art better understand the present invention, the applicant has carried out series of experiment research, to prove effect of the present invention:
One, antidepressant effect zoopery
This experiment adopts autonomic activities experiment, forces the experiments such as outstanding tail and forced swimming to launch to observe mice behavior depression, analyze, and by a series of index, the antidepressant effect of invention formulation is described.
1.1 laboratory animals and material
Animal: Kunming mouse, male and female dual-purpose, body weight 18-25g, Guiyang Medical College Animal House provides.
Medicine: invention formulation, the Chinese medicine extract obtained by Mylabris, Radix Ginseng, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Sparganii, Herba Scutellariae Barbatae, Rhizoma Curcumae, Fructus Corni, Fructus Ligustri Lucidi, Fel Ursi powder, Radix Glycyrrhizae according to the preparation method of embodiment 1-3.
1.2 experimental technique
Experiment grouping 60 mices are divided into cantharides to test low dose group, cantharides experiment high dose group and Normal group at random, often organize 20, by body weight medicinal liquid, gavage is carried out to mice, dosage: invention formulation low dose group 10ml/kg, invention formulation high dose group 30ml/kg, Normal group does not award medicine, normally raises, and carries out following three kinds of experiments respectively.
1.2.1 the continuous gavage of mice autonomic activities experiment mice 7 days, after last gavage 1h, put into XZC-4A toy autonomic activities analyzer (Shandong Academy of Medical Sciences's manufacture), after adapting to 3min, observe the movable number of times in 5min, and record result, in table 1.
1.2.2 the continuous gavage of Tail suspension test mice 7 days, is fixed on horizontal plane by mice tail end 2cm place after last gavage 1h, makes it be reversal of the natural order of things state, head destage face is about 30cm, surrounding is with plate isolation animal sight line, and the record dead time of mice in 6min, in table 2.
1.2.3 mouse forced swimming test rejects preliminary experiment failure, continuous gavage 7 days, and after last gavage 1h, mice is put into diameter 22cm, the bucket of depth of water 10cm, water temperature 25 DEG C (consistent with preliminary experiment), adapts to 2min, the dead time of mice in accumulative rear 4min, in table 3.
1. all experimental results of 4 statistical procedures all represent with x ± s, adopt SPSS statistical software to carry out one factor analysis of variance and rank test.
2. result
2. 1 invention formulation is on the impact of mice autonomic activities
Invention formulation two dosage groups equal not statistically significant compared with Normal group, the results are shown in Table 1.
Table 1 invention formulation is on the impact (x ± s) of mice autonomic activities
| Group | Dosage | Animal (only) | 5min autonomic activities time (s) |
| Normal group | ---- | 20 | 144.56±26.79 |
| Low dose group | 10ml/kg | 20 | 130.89±38.19 |
| High dose group | 30ml/kg | 20 | 157.67±32.51 |
2. 2 invention formulation are on the impact of Tail suspension test dead time
Invention formulation low dose group, high dose group obviously can shorten the tail-suspention test small mouse dead time (P<0.05 or 0.01), and high dose group better effects if, the results are shown in Table 2.
Table 2 invention formulation is on the impact (x ± s) of Tail suspension test dead time
| Group | Dosage | Animal (only) | 6min autonomic activities time (s) |
| Normal group | ---- | 20 | 116.11±45.73 |
| Low dose group | 10ml/kg | 20 | 81.33±45.10● |
| High dose group | 30ml/kg | 20 | 63.93±48.22●● |
Compare with Normal group, ● P < 0. 05, ● ● P < 0. 01, following table is same.
2. 3 invention formulation are on the impact of mouse forced swimming test dead time
Invention formulation low dose group, high dose group can obviously shorten the tail-suspention test small mouse dead time, and high dose group better effects if, the results are shown in Table 3.
Table 3 invention formulation is on the impact (x ± s) of mouse forced swimming test dead time
| Group | Dosage | Animal (only) | 4min autonomic activities time (s) |
| Normal group | ---- | 20 | 82.33±63.24 |
| Low dose group | 10ml/kg | 20 | 37.25±45.42 |
| High dose group | 30ml/kg | 20 | 35.45±51.40 |
Tail suspension test and forced swim test are for screening and observe the reliable experimental technique of antidepressant drug in Behavioral pharmacology experiment.Above experimental data shows, compared with testing with Normal group, the dead time that invention formulation is low, high dose all obviously can shorten outstanding tail and forced swim test small mouse, and its autonomic activities is not made significant difference, show that invention formulation has good antidepressant effect, and without central excitatory effect.
Two, the present invention is to the effect of tumor patient depression
1, physical data
120 routine tumor patients, main manifestations is depressed, no positive mental disorder and family history, and mind is clear, without understanding dysfunction.100 routine patients are divided into two groups at random.Treatment group 60 example, man 31 example, female 29 example, 48 ± 16 years old age; Matched group 60 example, man 30 example, female 30 example, 45 ± 15 years old age.
The diagnosis of depression, is evaluated by Psycs.To 120 routine respondents after being in hospital 1 week, according to the evaluation of Hamilton depression rating scale for depression (24 HANMD) methods of marking, methods of marking is: every point of 5 kinds of degree in 24 projects, nothing, gently, in, heavy, very heavy, score value is respectively 0, and 1,2,3,4 points, every score adds up.HANMD total score is more than or equal to 35 and is divided into major depression, and 20-35 are divided into modest depression, and 8-20 are divided into minor depressive, and the factor is divided into 7 factor structures to conclude.Treatment group major depression 9 example, accounts for 18%, and light to moderate depressed 41 examples, account for 82%; Matched group severe depression 6 example, accounts for 12%, and light to moderate depressed 44 examples, account for 88%.
2, Therapeutic Method
Treatment group: at random treatment group is divided into 6 groups, often organizes 10 people.Often group gives the embodiment of the present invention obtained pharmaceutical preparation, and administration kind, administering mode and dosage are as follows: the obtained invention formulation of embodiment 4 each 3 oral for group 1, every day 2 times; For group 2 after each 100ml of invention formulation that embodiment 5 obtains dilutes with 5% glucose 450ml, intravenous drip, once a day; The obtained invention formulation of embodiment 6 each 3 oral for group 3, every day 2 times; Each 3 bag mouth of invention formulation that embodiment 7 obtains are taken in group 4, every day 2 times; Each 3 bag mouth of invention formulation that embodiment 8 obtains are taken in group 5, every day 2 times; The obtained invention formulation of embodiment 9 each 2 dilute with 5% glucose 450ml after for group 6, intravenous drip, once a day; It within 14 days, is 1 course for the treatment of.Matched group only carries out psychotherapy.
3, criterion of therapeutical effect and therapeutic outcome
Hamilton depression rating scale for depression (24 HANMD) is adopted to evaluate curative effect.Recent healing O ~ 8 point, take a turn for the better 21 ~ 35 points by effective 9 ~ 20 points, invalid more than 35 points.The results are shown in Table 4, table 5.
The each group factor score value of table 4 compares (x ± s) unit: point
Before treatment, two groups of every factor score compare equal not statistically significant, have comparability.
Table 5 liang group symptom comparitive study unit: example
| n | Recent healing | Effective | Take a turn for the better | Invalid | Total effective rate | |
| Treatment group | 60 | 20 | 30 | 4 | 6 | 90.0（%） |
| Matched group | 60 | 12 | 18 | 19 | 11 | 81.0（%） |
The data that each group factor score value of table 4 compares illustrate, compared with matched group, after adopting invention formulation, every factor score all has reduction in various degree, and depressive symptom alleviates, and prompting invention formulation has the effect being better than psychotherapy's cancer-related depression card.
Table 5 liang group symptom comparitive study data illustrate, the total effective rate for the treatment of group is higher than matched group, and total effective rate is 90.0%, and its near-mid term cures, effective and totally 54 examples that take a turn for the better, and inefficiency accounts for 10%.And matched group, inefficiency accounts for 19%, points out compared with psychotherapy, the better efficacy of invention formulation treatment psychotherapy cancer-related depression card.
Detailed description of the invention:
Below, enumerate embodiment and the present invention is further described, but the present invention is not limited to following embodiment.
Embodiment 1:
(1) raw material is taken according to the following ratio:
Mylabris 3.97g, Radix Ginseng 9.92g, the Radix Astragali 49.58 g, Radix Et Caulis Acanthopanacis Senticosi 49.58g, Rhizoma Sparganii 15.83g, Herba Scutellariae Barbatae 59.5g, Rhizoma Curcumae 15.83g, Fructus Corni 19.83g, Fructus Ligustri Lucidi 19.83g, Fel Ursi powder 0.4g, Radix Glycyrrhizae 9.92g
(2) preparation method:
Above ten simply, and except Fel Ursi powder, Radix Ginseng, Fructus Corni, Fructus Ligustri Lucidi, Herba Scutellariae Barbatae are ground into fine powder, sieve for subsequent use; Mylabris chloroform soak extraction 3 times, each 95.2ml, soaks 72 hours, merge extractive liquid, reclaims chloroform, is concentrated into paste; The five tastes such as all the other Radixs Astragali decoct with water three times, 3 hours first times, the 2nd time 1.5 hours, 1 hour third time, collecting decoction, and filter, filtrate is concentrated into relative density and is about 1.20 (80 DEG C); Fel Ursi powder adds the fine powders such as above-mentioned thick paste, concentrated solution and Radix Ginseng, fully stirs evenly after adding 80 DEG C of water dissolutioies, obtained Chinese medicine extract.
Embodiment 2:
(1) raw material is taken according to the following ratio:
Mylabris 0.6g, Radix Ginseng 1.5g, the Radix Astragali 7.5 g, Radix Et Caulis Acanthopanacis Senticosi 7.5g, Rhizoma Sparganii 2.4g, Herba Scutellariae Barbatae 9.0g, Rhizoma Curcumae 2.4g, Fructus Corni 3g, Fructus Ligustri Lucidi 3g, Fel Ursi powder 0.05g, Radix Glycyrrhizae 1.5g
(2) preparation method:
Simply, except Fel Ursi powder, it is 60 object fine powders that Mylabris is pulverized to Fang Zhongshi, water extraction 4 times, the water that first time adds 22 times amount, soaks 30 minutes, extract 2 hours, second time adds the water of 15 times amount, extracts 1 hour, add the water of 12 times amount for the third time, extract 1 hour, add the water of 10 times amount for the 4th time, extract 1 hour, filter, merging filtrate, the 9 taste water extractions such as all the other Radix Ginsengs 3 times, first time adds 15 times of water gagings, soak 1 hour, extract 4 hours, second time adds 10 times of water gagings, extract 1.5 hours, third time adds 8 times of water gagings, extract 1.5 hours, filter, filtrate merges, being concentrated into relative density 60 DEG C of surveys is 1.15, let cool, adding ethanol to alcohol content is 60%, cold preservation 24 hours, filter, filtrate recycling ethanol, continue to be concentrated into relative density survey 60 DEG C time be 1.25 thick paste, add water to 70% of total amount, at 8 DEG C of cold preservation 48h, get supernatant, add Fel Ursi powder and make dissolving, add the mixing of Mylabris extracting solution, obtained Chinese medicine extract.
Embodiment 3:
(1) raw material is taken according to the following ratio:
Mylabris 6.0g, Radix Ginseng 15g, the Radix Astragali 100 g, Radix Et Caulis Acanthopanacis Senticosi 100g, Rhizoma Sparganii 24g, Herba Scutellariae Barbatae 100g, Rhizoma Curcumae 24g, Fructus Corni 30g, Fructus Ligustri Lucidi 30g, Fel Ursi powder 1.0g, Radix Glycyrrhizae 15g
(2) preparation method:
Preparation method is: simply, except Fel Ursi powder, powder of cantharide is broken into 60 object coarse powder to Fang Zhongshi, water extraction 3 times, the water that first time adds 20 times amount, soaks 40 minutes, extract 1.5 hours, second and third time adds the water of 15 times amount at every turn, extracts 1.0 hours, filter, merging filtrate, adds ethanol and reaches 80% to alcohol content, leave standstill, filter, filtrate reduced in volume becomes thick paste, adds the water of 8 times amount, stir, leave standstill, filter, filtrate is with the centrifugation 20 minutes of 10000 revs/min, centrifugal liquid concentrating under reduced pressure, dry, pulverize, obtain Mylabris extract;
Get the 9 taste medical materials such as all the other Radix Ginsengs, pulverize, extracted 3 times by decocting method, infusion process with the water of 10 times amount, merge extractive liquid, filter, filtrate reduced in volume becomes relative density to be the medicinal liquid of 1.10 at 60 DEG C, and adding ethanol to alcohol content is 60%, leave standstill 24 hours, filter, must precipitate and supernatant.Supernatant concentrating under reduced pressure becomes thick paste, adds the water of 10 times amount, stirs and leaves standstill, filter, processed good polyamide column on filtrate, first washes with water to colourless, use 50% ethanol elution of 8 times amount again instead, collect ethanol elution, decompression recycling ethanol, on concentrated solution, processed good macroporous adsorptive resins, first washes with water to colourless, then uses 60% ethanol elution instead, collect ethanol elution, concentrating under reduced pressure, dry, obtain total saponin extracts;
Get precipitation decompression cold drying, add appropriate distilled water and dissolve, add ethanol and reach 80% to alcohol content, leave standstill 24 hours, filter, precipitation adding distil water is dissolved into the solution of 1%, and cross hollow fiber column ultrafilter (molecular cut off is greater than 6000), ultrafiltrate is evaporated to dry; Or after getting secondary precipitate with ethanol, gained precipitation adds appropriate distilled water again and dissolves, and adds ethanol and reaches 75% to alcohol content, leave standstill 24 hours, filter, get precipitation with appropriate absolute ethanol washing 1-2 time, obtain polysaccharide active component;
Above-mentioned Mylabris extract, total saponin extracts, polysaccharide active component are fully mixed, dissolves with water for injection, then add Fel Ursi powder and make dissolving, obtained Chinese medicine extract.
Embodiment 4:
The Chinese medicine extract that in Example 1-3, any one method is obtained, dries, is ground into fine powder, incapsulates, make 6O00 grain, obtain FUFANG BANMAO JIAONANG agent below 80 DEG C, every dress 0.25g.
Embodiment 5:
The Chinese medicine extract that in Example 1-3, any one method is obtained, inject with water 100ml embedding in corresponding container, hot pressing (115 DEG C) sterilizing secondary, each 30 minutes, after cooling, paper pulp sucking filtration, filtrate is diluted to 1000ml with water for injection, is filtered by incipient fusion filter bulb, embedding, 115 DEG C of sterilizings 30 minutes again, obtain banmao complex injection, specification: 10ml/ props up.
Embodiment 6:
The Chinese medicine extract that in Example 1-3, any one method is obtained, 40 DEG C are dried to completely, fully mix, and granulate, with 16 mesh sieve granulate, adding 1% magnesium stearate is lubricant, and add microcrystalline Cellulose, amylum pregelatinisatum fully mixes, be pressed into 6000, film coating, obtains cantharides tablet, every 0.25g on chip.
Embodiment 7:
The Chinese medicine extract that in Example 1-3, any one method is obtained, 40 DEG C are dried to completely, abundant mixing, add in the Polyethylene Glycol M6000 of molten condition, stir, make it be uniformly dispersed, be incubated for subsequent use, by the melting substrate of mix homogeneously as keeping substrate in stirring in attemperator pill dripping machine, start is instiled, and makes the coolant of drop pill molding of liquid paraffin or silicone oil.Taken out from coolant by the drop pill made, carry out Rapid Cleaning with a small amount of dehydrated alcohol and be placed on forced air drying under 30 ~ 40 DEG C of conditions in the dish of stand, pick ball, glazing, packaging, obtains compound cantharis drop pill agent, specification: 0.25g/ bag.
Embodiment 8:
The Chinese medicine extract that in Example 1-3, any one method is obtained, 40 DEG C are dried to completely, fully mix, then to add dextrin to total amount be 1000g, pulverize, mixing, granulates, dry, granulate, packaging, every packed 0.25g, obtains cantharides granule, every packed 0.25g.
Embodiment 9:
The Chinese medicine extract that in embodiment 1-3, any one method is obtained, is dissolved in dehydrated alcohol, adds Cremophor EL, and mix and blend dissolves; Add in above-mentioned Chinese medicine extract alcoholic solution again after mannitol water for injection is dissolved, stirring and evenly mixing, be 3.54 with dilute hydrochloric acid adjust pH, add water for injection be stirred to Chinese medicine extract be dissolved to solution clarification, add the active carbon of supplementary material total amount 0.1%, stirring at room temperature 20 minutes, by 0.8 μm of filter membrane coarse filtration, filtrate injects water to 6000ml(routine prescription amount), use 0.22 μm of filter membrane fine straining again, be sub-packed in cillin bottle, put into freeze dryer and carry out lyophilizing, obtain injection use compound Mylabris lyophilized preparation 1000, specification: 30mg/ props up.
Claims (6)
1. the purposes of a cantharides Chinese medicine composition in preparation medicament for treatment of depression, it is characterized in that: described compositions, according to listed as parts by weight, be prepared from through extracting by Mylabris 3.97 parts, Radix Ginseng 9.92 parts, the Radix Astragali 49.58 parts, Radix Et Caulis Acanthopanacis Senticosi 49.58 parts, Rhizoma Sparganii 15.83 parts, Herba Scutellariae Barbatae 59.5 parts, Rhizoma Curcumae 15.83 parts, Fructus Corni 19.83 parts, Fructus Ligustri Lucidi 19.83 parts, Fel Ursi powder 0.4 part, 9.92 parts, Radix Glycyrrhizae.
2. the purposes of a compound mylabris preparation in preparation medicament for treatment of depression, it is characterized in that: this compound mylabris preparation adds the pharmaceutically conventional carrier of at least one by cantharides Chinese medicine composition described in claim 1 and adopts conventional method to be prepared from, and carrier is selected from filler, binding agent, disintegrating agent, surfactant, absorption enhancer and lubricant.
3. compound mylabris preparation is preparing the purposes in medicament for treatment of depression according to claim 2, and it is characterized in that, this compound mylabris preparation is capsule, injection, tablet, drop pill, granule, Emulsion, solution, suspending agent.
4. the purposes of compound mylabris preparation in preparation medicament for treatment of depression according to claim 2, is characterized in that: the route of administration of this compound mylabris preparation is oral, percutaneous, vein or intramuscular injection.
5. compound mylabris preparation is preparing the purposes in medicament for treatment of depression according to claim 3, and it is characterized in that, this compound mylabris preparation is capsule.
6. according to the purposes of the arbitrary described compound mylabris preparation of claim 3-5 in preparation medicament for treatment of depression, it is characterized in that, the purposes of described compound mylabris preparation in preparation treatment cancer-related antidepressant agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210159099.0A CN103417906B (en) | 2012-05-22 | 2012-05-22 | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210159099.0A CN103417906B (en) | 2012-05-22 | 2012-05-22 | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417906A CN103417906A (en) | 2013-12-04 |
| CN103417906B true CN103417906B (en) | 2015-09-09 |
Family
ID=49643646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210159099.0A Active CN103417906B (en) | 2012-05-22 | 2012-05-22 | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417906B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105769876B (en) * | 2016-03-08 | 2019-01-29 | 上海中医药大学 | The medical usage of Bile acid and bear gall |
| CN105920447A (en) * | 2016-06-12 | 2016-09-07 | 贵州神奇药物研究院 | Antidepressant health product and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100581582C (en) * | 2007-05-21 | 2010-01-20 | 贵州益佰制药股份有限公司 | Compound oral taking preparation of cantharis, and preparation method |
-
2012
- 2012-05-22 CN CN201210159099.0A patent/CN103417906B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417906A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078520B (en) | Chinese medicinal preparation for treating nervous headache and preparation method thereof | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN101972385B (en) | Method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN103417906B (en) | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof | |
| CN106038637A (en) | Pharmaceutical composition for treating breast cancer | |
| CN105535391A (en) | Medicine composition for treating pneumonia | |
| CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN113599471A (en) | Traditional Chinese medicine granules for primary lung cancer and production process thereof | |
| CN101224226B (en) | Novel clinical uses of big nilgiri nettle | |
| CN103656469A (en) | Compound cantharides traditional Chinese medicine composition and use of preparation thereof in preparation of medicine for treating radiation-induced pulmonary injury | |
| CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN104435772A (en) | Hawthorn-containing pharmaceutical composition for reducing blood fat | |
| CN103417607A (en) | Applications of traditional Aidi Chinese medicine composition and preparations thereof in preparing drugs for curing depression | |
| CN100502912C (en) | Medicine for treating deficiency syndrome, its preparing process and usage | |
| CN103479868B (en) | Traditional Chinese medicine for treating apprehensive and cowardly arrhythmia and preparation method | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631486B (en) | Health care composition | |
| CN1931285B (en) | Chinese medicine composition and its preparation process | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |